Founder Director at MEDICIS labs and ClinSync, India
Suresh Attili, a renowned physician and scientist who is working on both the basic research and clinical research in hematology/Oncology. He graduated from IMS and continued to work in prestigious institutes like AIIMS Delhi at various positions. His clinical expertise can be exemplified by some of his achievements like first autologous transplantation of India using GM- CSF. He had 74 publications in peer reviewed journals and is a sought after reviewer for various international journals such as American Journal of Clinical Oncology, leukemia research and others. He authored textbooks of international standards like American Association of HIV medicine in 2007. He is winner of many awards and to name a few, Scholar in training award by American association of Cancer research (AACR) 2007, the “young oncologist supportive award for developing nations” by the European society, 2008 “Department of Science and technology-Govt of India” 2006. He is also a Principal Investigator for more than 56 international clinical trials and is the youngest investigator from India to be audited by US FDA and got “no action indicated” for his study on Temozolomide. He is also a member of Ethics committee at MNJ institute of Oncology and also a data safety monitoring committee member for Phase I [NCE] trial reviewing for DCGI. Besides being steering committee member for ASPECCT [AMGEN project] like projects, he is also advisor for the manuscript and medical writing for major pharmaceutical companies. He is currently working as a Consultant Medical Oncologist and Hematologist, at APOLLO hospital, India and also visiting on request as honorary Associate Professor at esteemed institutes like UBM, etc
The medicinal plant products have since been used in the supportive oncology both off label and with proper prescription in Indian subcontinent, due to wide availability of alternative form of medicines predominantly ayurveda and other naturopathy. The recent interest of the modern medicine in the field of supportive oncology can be reflected by few examples of ongoing trails like 1. “NCT01337089” in cancer pain [cannabis] 2. “NCT00046709” in cancer pain [marijuana] 3. “NCT01733212”, “NCT00040742” ginger in caner induced nausea 4. “NCT01344538” for colorectal cancer prevention Which mainly deal with reversing/normalizing the altered balance represented as clinical toxicity like nausea, pain etc. and also in prevention of few common malignancies like colorectal cancers. The talk will be in detail about the scientific approaches needed to be adopted by the potential confounders as well as measures to abridge the alternative with modern medicine including the art of designing appropriate clinical projects.